Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

2.

Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.

Tan C, Dannull J, Nair SK, Ding E, Tyler DS, Pruitt SK, Lee WT.

J Surg Res. 2013 Dec;185(2):904-11. doi: 10.1016/j.jss.2013.06.045. Epub 2013 Jul 17.

PMID:
23891424
3.

Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.

Yamamoto M, Kamigaki T, Yamashita K, Hori Y, Hasegawa H, Kuroda D, Moriyama H, Nagata M, Ku Y, Kuroda Y.

Oncol Rep. 2009 Aug;22(2):337-43.

PMID:
19578774
4.

Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.

Rosalia RA, Štěpánek I, Polláková V, Šímová J, Bieblová J, Indrová M, Moravcová S, Přibylová H, Bontkes HJ, Bubeník J, Sparwasser T, Reiniš M.

Immunobiology. 2013 Jun;218(6):851-9. doi: 10.1016/j.imbio.2012.10.012. Epub 2012 Oct 26.

PMID:
23182710
5.

CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.

Johnson BD, Jing W, Orentas RJ.

J Immunother. 2007 Feb-Mar;30(2):203-14.

PMID:
17471167
6.

Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.

Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg NM, Klasen IS, Hilbrands LB, Figdor CG, de Vries IJ, Adema GJ.

Clin Cancer Res. 2010 Oct 15;16(20):5067-78. doi: 10.1158/1078-0432.CCR-10-1757. Epub 2010 Aug 24.

8.

Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity.

Zhou S, Chen L, Qin J, Li R, Tao H, Zhen Z, Chen H, Chen G, Yang Y, Liu B, She Z, Zhong C, Liang C.

PLoS One. 2013 Sep 2;8(9):e73952. doi: 10.1371/journal.pone.0073952. eCollection 2013. Erratum in: PLoS One. 2014;9(3):e93126. Chen, Long [added]; Qin, Jie [added]; Li, Rilun [added]; Liu, Binbin [added]; She, Zhenjue [added]; Zhong, Cuiping [added]; Liang, Chunmin [added].

9.

Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.

Croce M, Corrias MV, Orengo AM, Brizzolara A, Carlini B, Borghi M, Rigo V, Pistoia V, Ferrini S.

Int J Cancer. 2010 Sep 1;127(5):1141-50. doi: 10.1002/ijc.25140.

10.

DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.

Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW.

Neuro Oncol. 2009 Oct;11(5):529-42. doi: 10.1215/15228517-2009-004. Epub 2009 Mar 31.

11.

Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.

Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, Wang Y, Cheng X, Li YQ, Xia JC, Masucci M, Zeng YX.

Cancer Immunol Immunother. 2007 Oct;56(10):1597-604. Epub 2007 Apr 18.

PMID:
17440723
12.
13.

Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.

Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S.

Oncol Rep. 2008 May;19(5):1265-70.

PMID:
18425386
14.

Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.

Zhang M, Berndt BE, Chen JJ, Kao JY.

J Immunol. 2008 Sep 1;181(5):3690-7. Erratum in: J Immunol. 2008 Nov 15;181(10):7428.

15.

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.

Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T.

Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5.

16.

In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.

Setiady YY, Coccia JA, Park PU.

Eur J Immunol. 2010 Mar;40(3):780-6. doi: 10.1002/eji.200939613.

17.

Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

Tanaka H, Shimizu K, Hayashi T, Shu S.

Cell Immunol. 2002 Nov;220(1):1-12.

PMID:
12718934
18.

Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.

Tanaka H, Tanaka J, Kjaergaard J, Shu S.

J Immunother. 2002 May-Jun;25(3):207-17.

PMID:
12000862
19.

Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.

Lee H, Park HJ, Sohn HJ, Kim JM, Kim SJ.

J Surg Res. 2011 Jul;169(1):e43-50. doi: 10.1016/j.jss.2011.03.067. Epub 2011 Apr 21.

PMID:
21571303
20.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899

Supplemental Content

Support Center